Based on these findings, AFP response in patients with baseline AFP ≥ 10 ng/mL, baseline ALBI score in patients with level <10 ng/mL, and change in ALBI score from baseline to that estimated one month post-treatment may have a great impact on OR in patients with HCC undergoing lenvatinib treatment. The gene discussed is AFP; the disease is hepatocellular carcinoma.